share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Obenshain Andrew

SEC announcement ·  Feb 7 05:13
Summary by Futu AI
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 1,879 shares of common stock on February 5, 2024. The transaction was carried out in the open market with a sale price of $0.9025 per share, resulting in a total value of approximately $1,695.80. Following the sale, Obenshain's direct holdings in the company amount to 286,093 shares of common stock.
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 1,879 shares of common stock on February 5, 2024. The transaction was carried out in the open market with a sale price of $0.9025 per share, resulting in a total value of approximately $1,695.80. Following the sale, Obenshain's direct holdings in the company amount to 286,093 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.